Gelesis Holdings (Gelesis Holdings) Total Assets : $95.88 Mil (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings Total Assets?

Gelesis Holdings's Total Assets for the quarter that ended in Jun. 2023 was $95.88 Mil.

During the past 12 months, Gelesis Holdings's average Total Assets Growth Rate was -22.60% per year.

Total Assets is connected with ROA %. Gelesis Holdings's annualized ROA % for the quarter that ended in Jun. 2023 was -31.57%. Total Assets is also linked to Revenue through Asset Turnover. Gelesis Holdings's Asset Turnover for the quarter that ended in Jun. 2023 was 0.01.

Gelesis Holdings Total Assets Historical Data

The historical data trend for Gelesis Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings Total Assets Chart

Gelesis Holdings Annual Data

Trend

Dec21

Dec22

Total Assets

146.30

103.32

Gelesis Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Assets	Get a 7-Day Free Trial					138.97	130.52	103.32	98.78	95.88

Gelesis Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Gelesis Holdings's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	-12.466	+	115.79
	=	103.32

Gelesis Holdings's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	-18.625	+	114.5
	=	95.88

Gelesis Holdings (OTCPK:GLSHQ) Total Assets Explanation

Total Assets is connected with ROA %.

Gelesis Holdings's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	-30.724	/	( (98.78	+	95.875)	/ 2 )
	=	-30.724	/	97.3275
	=	-31.57 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Gelesis Holdings's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	1.107	/	( (98.78	+	95.875)	/ 2 )
=	1.107	/	97.3275
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Gelesis Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website

https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Executives

Raju S Kucherlapati	director	77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc	10 percent owner	195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd	10 percent owner	SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino	officer: Lead Project Scientist	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks	director	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass	officer: Chief Op. & Comm. Officer	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette	officer: Chief Scientific Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman	director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider	officer: Chief Medical Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher	director	2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech	10 percent owner	6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc	10 percent owner	142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar	director, officer: President & CEO	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms	10 percent owner	C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510